Schroder Investment Management Group Editas Medicine, Inc. Transaction History

Schroder Investment Management Group

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$14.88 - $32.78 $345,186 - $760,430	-23,198 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$22.49 - $26.81 $35,646 - $42,493	1,585 Added 7.33%	23,198 $522,000
Q2 2019 Aug 08, 2019	SELL	$20.48 - $27.76 $188,866 - $256,002	-9,222 Reduced 29.91%	21,613 $535,000
Q4 2018 Feb 14, 2019	BUY	$18.19 - $31.79 $165,201 - $288,716	9,082 Added 41.75%	30,835 $701,000
Q2 2018 Aug 13, 2018	BUY	$31.4 - $41.01 $683,044 - $892,090	21,753 New	21,753 $780,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $82.5M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

Stay updated on Schroder Investment Management Group with notifications on news.